GSK receives offer for its thrombosis brands and related manufacturing site

GSK receives offer for its thrombosis brands and related manufacturing site

Issued: Tuesday 18 June 2013, London UK

GlaxoSmithKline (LSE: GSK) has today received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited. A period of exclusivity has been agreed with Aspen and GSK will respond to the offer subject to consultation with employees and the relevant works councils.

The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra® and Fraxiparine® (excluding China, India and Pakistan) brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees.

The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

Statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.


^ Back to top